Cargando…

SCY-078 Demonstrates Significant Antifungal Activity in a Murine Model of Invasive Aspergillosis

BACKGROUND: Azoles are the most common anti-fungal agents for the treatment of Aspergillus infections. Echinocandins have demonstrated utility in Aspergillus infections, but are limited in use due to a lack of oral bioavailability. SCY-078 is a novel, oral and intravenous (IV), triterpenoid glucan s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Borroto-Esoda, Katyna, Barat, Stephen, Angulo, David, Holden, Kirsty, Warn, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631313/ http://dx.doi.org/10.1093/ofid/ofx163.1207

Ejemplares similares

SCY-078 Demonstrates Significant Tissue Penetration in Rats and Mice Following Oral or IV Administration
por: Barat, Stephen, et al.
Publicado: (2017)

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017)

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

Evaluation of the Antifungal Activity of the Novel Oral Glucan Synthase Inhibitor SCY-078, Singly and in Combination, for the Treatment of Invasive Aspergillosis
por: Ghannoum, M., et al.
Publicado: (2018)

SCY-078 Is Fungicidal against Candida Species in Time-Kill Studies
por: Scorneaux, Bernard, et al.
Publicado: (2017)

Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
por: Wring, Stephen A., et al.
Publicado: (2017)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
por: Larkin, Emily, et al.
Publicado: (2017)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021)

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
por: Quindós, Guillermo, et al.
Publicado: (2022)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

1054. Activity of a Anti-staphylococcal Lysin, LSVT-1701: In vitro Susceptibility of Staphylococcus aureus and Coagulase-Negative Staphylococci (CoNS) Global Clinical Isolates (2002 to 2019)
por: Huang, David, et al.
Publicado: (2021)

1071. Efficacy of Anti-Staphylococcal Lysin, LSVT-1701, in Combination with Daptomycin in Experimental Left-Sided Infective Endocarditis (IE) Due to Methicillin-Resistant Staphylococcus aureus (MRSA)
por: Huang, David, et al.
Publicado: (2021)

1346. The Tetrazole VT-1598 Is Efficacious in a Murine Model of Invasive Aspergillosis with a PK/PD Expected of a Mold-Active CYP51 Inhibitor
por: Garvey, Edward P, et al.
Publicado: (2018)

Antifungal Treatments Delineate a Correlation between Cathepsins and Cytokines in Murine Model of Invasive Aspergillosis
por: Mittal, Ashwani, et al.
Publicado: (2013)

P078 Baseline antifungal usage patterns and knowledge regarding management of invasive fungal infections as a part of a multidisciplinary antifungal stewardship (AFS) program
por: Sachdev, Janya, et al.
Publicado: (2022)

Modeling Invasive Aspergillosis: How Close Are Predicted Antifungal Targets?
por: Walsh, Thomas J., et al.
Publicado: (2020)

82. Incidence rates of invasive aspergillosis among lung transplant recipients in timeperiods with universal and targeted antifungal prophylaxis - a nationwide cohort study
por: Crone, Cornelia G, et al.
Publicado: (2022)

The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action study
por: Feng, Joy Y, et al.
Publicado: (2009)

Invasive Aspergillosis by Aspergillus flavus: Epidemiology, Diagnosis, Antifungal Resistance, and Management
por: Rudramurthy, Shivaprakash M., et al.
Publicado: (2019)

TREM1 regulates antifungal immune responses in invasive pulmonary aspergillosis
por: Bernal-Martínez, L, et al.
Publicado: (2021)

Diol-Based Polymer Microparticles for Treatment of Cutaneous Aspergillosis in an Immunocompromised Murine Model
por: Tatara, Alexander, et al.
Publicado: (2017)

A Tet-Off gene expression system for validation of antifungal drug targets in a murine invasive pulmonary aspergillosis model
por: Peng, Yutian, et al.
Publicado: (2018)

974. PD-1 Immune Checkpoint Blockade Improves Survival and Promotes Fungal Clearance in an Immunosuppressed Murine Invasive Pulmonary Aspergillosis (IPA) Model
por: Wurster, Sebastian, et al.
Publicado: (2019)

Epidemiology and antifungal resistance in invasive aspergillosis according to primary disease - review of the literature
por: Mayr, A, et al.
Publicado: (2011)

Efficacy and safety of combination antifungal therapy in Korean haematological patients with invasive aspergillosis
por: Lee, Dong‐Gun, et al.
Publicado: (2019)

AB078. Knockdown of SPC25 inhibits cell proliferation and cycle progression in prostate cancer
por: Cui, Feilun, et al.
Publicado: (2017)

APX001 Is Effective in the Treatment of Murine Invasive Pulmonary Aspergillosis
por: Gebremariam, Teclegiorgis, et al.
Publicado: (2019)

Efficacy of Ebselen Against Invasive Aspergillosis in a Murine Model
por: Sakita, Karina Mayumi, et al.
Publicado: (2021)

Epidemiology and Outcomes of Hospitalizations with Invasive Aspergillosis in the United States, 2010–2013
por: Zilberberg, Marya D, et al.
Publicado: (2017)

967. Inhibition of Host Neuraminidase Increases Susceptibility to Invasive Pulmonary Aspergillosis
por: Van De Veerdonk, Frank, et al.
Publicado: (2018)

1707. Invasive Pulmonary Aspergillosis in Patients with Severe Fever with Thrombocytopenia Syndrome
por: Bae, Seongman, et al.
Publicado: (2019)

1690. Risk Factors of Invasive Aspergillosis in Systemic Lupus Erythematosus Patients
por: Kunawathanakul, Sithichai, et al.
Publicado: (2019)

1699. Safety and Outcomes of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric Patients
por: Arrieta, Antonio C, et al.
Publicado: (2023)

Primary Aspergillosis
Publicado: (1915)

Sa078 CLINICAL AND LABORATORY MARKERS DO NOT PREDICT DEEP HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS
por: Sharma, Disha, et al.
Publicado: (2021)

451 Case Finding for Invasive Aspergillosis in Children
por: Salsgiver, Elizabeth, et al.
Publicado: (2014)

Potential antifungal targets based on histones post-translational modifications against invasive aspergillosis
por: Li, Yiman, et al.
Publicado: (2022)

GR-2397: Review of the Novel Siderophore-like Antifungal Agent for the Treatment of Invasive Aspergillosis
por: Shaw, Karen Joy
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_18sjj9ne66930n4t0qp4qjo1h4